Evogene Ltd.
No SEC Form 4 filings for $EVGN in the last 30 days.
See all $EVGN insider activity →EverGen Infrastructure Corp. reported its highest quarterly Renewable Natural Gas production in Q3 2026, up 8% year over year. The company did not disclose revenue or volume figures.
Evogene Ltd. (EVGN) agreed with Pure Capital Group to resolve disputes and reconstitute its board. Two current directors will be replaced by Pure Capital nominees, with shareholder approval. Pure Capital will withdraw its tender offer and enter a 60-day standstill period. Evogene's board approved the agreement, citing shareholder interests.
Evogene (NASDAQ: EVGN) received a 180-day extension from Nasdaq to comply with the minimum $1.00 bid price requirement, ending March 29, 2027. The company must maintain a closing bid price of at least $1.00 for 10 consecutive days to regain compliance. Evogene plans to explore options like a reverse share split if needed. Trading continues on Nasdaq under 'EVGN'.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning EVGN (Evogene Ltd.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent EVGN coverage spans financial news, insider activity and earnings.
Operational update with modest production increase; limited immediate price impact.
The board change and tender offer withdrawal may cause short-term price pressure as investors assess governance risk.
The extension highlights ongoing compliance risk and may keep downward pressure on the stock.
Small insider purchase signals modest confidence from senior management.
Potential short-term volatility due to board election and modest capital raise; limited immediate price impact.
AlphAI scores every news story that mentions EVGN with an AI model for sentiment and relevance, and aggregates insider trades from Evogene Ltd.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
EverGen Infrastructure Corp. reported its highest quarterly Renewable Natural Gas production in Q3 2026, up 8% year over year. The company did not disclose revenue or volume figures.
1 min readEvogene Ltd. (EVGN) agreed with Pure Capital Group to resolve disputes and reconstitute its board. Two current directors will be replaced by Pure Capital nominees, with shareholder approval. Pure Capital will withdraw its tender offer and enter a 60-day standstill period. Evogene's board approved the agreement, citing shareholder interests.
2 min readEvogene (NASDAQ: EVGN) received a 180-day extension from Nasdaq to comply with the minimum $1.00 bid price requirement, ending March 29, 2027. The company must maintain a closing bid price of at least $1.00 for 10 consecutive days to regain compliance. Evogene plans to explore options like a reverse share split if needed. Trading continues on Nasdaq under 'EVGN'.
1 min readTarcic Gabi (Chief Development Officer) purchased 1,129 shares of Evogene Ltd. (EVGN) at $0.60 on 2026-06-04.
1 min readEvogene (EVGN) reported Q2 2026 earnings, highlighting strategic changes and financial results. The board addressed a demand from dissident shareholders to replace them, emphasizing their transformation into an AI-driven company and securing key drug development agreements. The company reduced headcount and cash burn, raised capital, and monetized assets. Management expressed confidence in their strategy and long-term value creation, while preparing to add new board members.
2 min readEvogene Ltd. reported a 62% year-over-year net loss improvement to $1.8M in Q2 2026, driven by reduced operating expenses. The company restructured, cutting headcount and lowering cash burn. It monetized non-core assets and upgraded its ChemPass AI platform. Management aims to transition to preclinical trials and expects revenue growth from partnerships and milestone payments. Geopolitical risks in Israel and the Middle East were highlighted. Candidate tickers: EVGN.
3 min readEvogene Ltd. (EVGN) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Evogene Reports Second Quarter and First Half 2026 Financial Results · Company continues strategic transformation, initiated in 2025, into a focused, AI-driven computational chemistry company, with significant progress across pharmaceutical and agricultural product d
2 min readEvogene Ltd. (Nasdaq: EVGN, TASE: EVGN) said Chairman Nir Nimrodi will join its Aug. 18, 2026 quarterly results call to address a situation involving dissident shareholders. The company plans to share its perspective and discuss potential implications for Evogene and shareholders. The call is scheduled for 9:00 AM ET.
2 min readRECANATI LEON purchased 460,000 shares of Evogene Ltd. (EVGN) at $0.64 ($0.29M total) on 2026-08-11.
1 min readRECANATI LEON purchased 800,000 shares of Evogene Ltd. (EVGN) at $0.50 ($0.40M total) on 2026-08-04.
1 min read
